Understanding GPR55: A Potential Drug Target and Biomarker for Various Diseases

Target Name: GCSH

NCBI ID: G2653

GCSH

Understanding GPR55: A Potential Drug Target and Biomarker for Various Diseases

GCSH (GCSH_HUMAN), also known as G-protein-coupled receptor GPR55, is a protein that is expressed in various tissues of the human body. GPR55 is a member of the G-protein-coupled receptor family, which is a large family of transmembrane proteins that play an important role in cellular signaling.

GPR55 is a key regulator of the immune response, and it has been shown to play a crucial role in the regulation of inflammation and inflammation-related diseases. GPR55 is also involved in the regulation of pain perception and neurotransmitter signaling, and it has been implicated in a number of neuropsychiatric and neurological disorders.

Due to its involvement in a wide range of physiological processes, GPR55 has been identified as a potential drug target. Researchers have been investigating the use of GPR55 as a potential therapeutic target for a variety of conditions, including pain, neurodegenerative diseases, and psychiatric disorders.

One of the main advantages of GPR55 as a drug target is its high degree of sensitivity to small molecules. This is because GPR55 is a structurally simple protein that is composed of a single transmembrane domain, which makes it relatively easy to modify. Additionally, GPR55 has a relatively short half-life, which allows for rapid elimination from the body.

Despite its potential as a drug target, GPR55 has not yet been approved for use by the FDA. There are several reasons for this. First, GPR55 is not a highly potent drug target, and it is difficult to optimize for maximum efficacy. Second, GPR55 is expressed in many different tissues of the body, which can make it difficult to target without unintended consequences. Finally, GPR55 is a protein that is involved in a wide range of physiological processes, which can make it difficult to study and understand its mechanisms of action.

In addition to its potential as a drug target, GPR55 is also a potential biomarker for a number of diseases. For example, GPR55 has been shown to be involved in the regulation of pain perception, and it has been used as a biomarker for the diagnosis of neurodegenerative diseases. Additionally, GPR55 has been shown to be involved in the regulation of neurotransmitter signaling, which can make it a useful biomarker for the diagnosis of psychiatric disorders.

Overall, GPR55 is a protein that has the potential to be a drug target and a biomarker for a variety of diseases. Further research is needed to fully understand its mechanisms of action and to develop safe and effective treatments.

Protein Name: Glycine Cleavage System Protein H

Functions: The glycine cleavage system catalyzes the degradation of glycine. The H protein (GCSH) shuttles the methylamine group of glycine from the P protein (GLDC) to the T protein (GCST)

The "GCSH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCSH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets